M
Marina De Smet
Researcher at Merck & Co.
Publications - 14
Citations - 1746
Marina De Smet is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pharmacodynamics & Sitagliptin. The author has an hindex of 12, co-authored 13 publications receiving 1661 citations.
Papers
More filters
Journal ArticleDOI
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes
Gary A. Herman,Arthur J. Bergman,Catherine Stevens,Paul Kotey,Bingming Yi,Peng Zhao,Bruno Dietrich,George Golor,Andreas Schrodter,Bart Keymeulen,Kenneth C. Lasseter,Mark Kipnes,Karen Snyder,Deborah Hilliard,Michael Tanen,Caroline Cilissen,Marina De Smet,Inge De Lepeleire,Kristien Van Dyck,Amy Qiu Wang,Wei Zeng,Michael J. Davies,Wesley Tanaka,Jens J. Holst,Carolyn F. Deacon,Keith Gottesdiener,John A. Wagner +26 more
TL;DR: In patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses was associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitgliptin concentration of 100 nm or greater and an augmentation of active GLP-1 and GIP levels of 2-fold or higher after an OGTT.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
Gary A. Herman,Cathy Stevens,Kristien Van Dyck,Arthur J. Bergman,Bingming Yi,Marina De Smet,Karen Snyder,Deborah Hilliard,Michael Tanen,Wesley Tanaka,Amy Qiu Wang,Wei Zeng,D.G. Musson,Gregory A. Winchell,Michael J. Davies,Steven Ramael,Keith Gottesdiener,John A. Wagner +17 more
TL;DR: Sitagliptin is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP‐IV) currently in phase III development for the treatment of type 2 diabetes.
Journal ArticleDOI
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Arthur J. Bergman,Catherine Stevens,YanYan Zhou,Bingming Yi,Martine Laethem,Marina De Smet,Karen Snyder,Deborah Hilliard,Wesley Tanaka,Wei Zeng,Michael Tanen,Amy Qiu Wang,Li Chen,Gregory A. Winchell,Michael J. Davies,Steven Ramael,John A. Wagner,Gary A. Herman +17 more
TL;DR: Assessment of the pharmacokinetic and pharmacodynamic properties and tolerability of multiple oral once-daily or twice-daily doses of sitagliptin found a finding consistent with near-maximal acute glucose lowering in preclinical studies.
Journal ArticleDOI
Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869
Simon Van Belle,Michael R. Lichinitser,Rudolph M. Navari,August Garin,Marc Decramer,Alain Riviere,Myo Thant,Elmer Brestan,Binh Bui,Krista Eldridge,Marina De Smet,Nicole Michiels,Rick R. Reinhardt,Alexandra D. Carides,Judith K. Evans,Barry J. Gertz +15 more
TL;DR: This data indicates that antiemetic therapy with a triple combination of the neurokinin‐1 receptor antagonist MK‐869, a serotonin (5‐HT3) antagonist, and dexamethasone provides enhanced control of cisplatin‐induced emesis compared with standard therapy regimens.
Journal ArticleDOI
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
Marian Iwamoto,Larissa Wenning,Amelia S. Petry,Martine Laethem,Marina De Smet,James Kost,Sheila Breidinger,Eric Mangin,Neal Azrolan,Howard E. Greenberg,Wouter Haazen,Julie A. Stone,Keith Gottesdiener,John A. Wagner +13 more
TL;DR: Though plasma concentrations of raltegravir were moderately to weakly reduced by efavirenz, the degree of this reduction was not clinically meaningful and there were no substantial differences in the time to maximum concentration in plasma or the half-life.